In this insightful discussion, Amer Zeidan from Yale and Rena Buckstein from Sunnybrook share their expert views on treating lower-risk myelodysplastic syndromes (MDS). They highlight the importance of accurate diagnosis with bone marrow examinations and prognostic tools. Guillermo Garcia-Manero from MD Anderson dives into innovative treatments like erythropoiesis-stimulating agents and Luspatercept, while Andrew Brunner emphasizes the complexities of dosing. They advocate for improved strategies and collaboration to enhance patient care and outcomes.

Experts discuss novel agents like luspatercept and imetelstat for LR-MDS post ESA failure. They explore HMA use, future trials, and early intervention benefits for patients, shedding light on changing treatment landscapes and improving QoL.

Experts Amer Zeidan and Sanam Loghavi discuss the updated ICC and WHO classifications for MDS. They explore the overlap and differences between the two systems and highlight the challenges in classifying MDS. The podcast also emphasizes the importance of a comprehensive report and the potential of AI in generating such reports. The significance of a uniform classification for MDS and its impact on clinical practice is highlighted, along with the need for improved treatments. Lastly, the podcast emphasizes the importance of providing accurate patient education resources and recognizing genetic abnormalities morphologically.